Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026)
Avalo Therapeutics (AVTX) posted Non Operating Income of $1.3 million for Q1 2026, up 115.03% on a QoQ basis from -$8.5 million in Q4 2025, and up 11.76% year-over-year from $1.1 million in Q1 2025.
Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Non Operating Income history runs 13 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- Quarterly Non Operating Income rose 11.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 104.09% YoY) and the FY2025 annual result came in at -$5.2 million, down 115.43% from the prior year.
- Non Operating Income was $1.3 million for Q1 2026 at Avalo Therapeutics, up from -$8.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $108.0 million in Q2 2024 and bottomed at -$21.9 million in Q4 2024.
- A 5-year average of $6.5 million and a median of -$898000.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 7094.12% — and 2024, when it soared 10529.05%.
- Avalo Therapeutics' Non Operating Income stood at -$949000.0 in 2022, then jumped by 45.31% to -$519000.0 in 2023, then plunged by 4122.35% to -$21.9 million in 2024, then soared by 61.05% to -$8.5 million in 2025, then soared by 115.03% to $1.3 million in 2026.
- Business Quant data shows AVTX's Non Operating Income at $1.3 million in Q1 2026, -$8.5 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | -8.54 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | -21.91 Mn |
| Sep 30, 2024 | 35.88 Mn |
| Jun 30, 2024 | 108.05 Mn |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | -519,000.00 |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | -1.04 Mn |
| Mar 31, 2023 | -949,000.00 |
| Dec 31, 2022 | -949,000.00 |
| Sep 30, 2022 | -898,000.00 |
| Jun 30, 2022 | -1.15 Mn |
| Mar 31, 2022 | -1.19 Mn |
| Dec 31, 2021 | -1.18 Mn |
| Sep 30, 2021 | -1.00 Mn |
| Jun 30, 2021 | -239,000.00 |